- Home
- AXTA vs BPMC Comparison
AXTA vs BPMC Comparison
Compare AXTA & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXTA
- BPMC
- Stock Information
- Founded
- AXTA 1910
- BPMC 2008
- Country
- AXTA United States
- BPMC United States
- Employees
- AXTA N/A
- BPMC N/A
- Industry
- AXTA Paints/Coatings
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- AXTA Consumer Discretionary
- BPMC Health Care
- Exchange
- AXTA Nasdaq
- BPMC Nasdaq
- Market Cap
- AXTA 7.2B
- BPMC 5.8B
- IPO Year
- AXTA 2014
- BPMC 2015
- Fundamental
- Price
- AXTA $32.85
- BPMC $97.51
- Analyst Decision
- AXTA Buy
- BPMC Buy
- Analyst Count
- AXTA 15
- BPMC 21
- Target Price
- AXTA $41.53
- BPMC $124.05
- AVG Volume (30 Days)
- AXTA 2.6M
- BPMC 880.5K
- Earning Date
- AXTA 05-07-2025
- BPMC 05-01-2025
- Dividend Yield
- AXTA N/A
- BPMC N/A
- EPS Growth
- AXTA 83.38
- BPMC N/A
- EPS
- AXTA 2.05
- BPMC N/A
- Revenue
- AXTA $5,244,000,000.00
- BPMC $562,121,000.00
- Revenue This Year
- AXTA $2.69
- BPMC $44.85
- Revenue Next Year
- AXTA $3.65
- BPMC $32.06
- P/E Ratio
- AXTA $16.00
- BPMC N/A
- Revenue Growth
- AXTA 0.96
- BPMC 99.19
- 52 Week Low
- AXTA $27.70
- BPMC $73.04
- 52 Week High
- AXTA $41.66
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- AXTA 53.85
- BPMC 57.71
- Support Level
- AXTA $30.89
- BPMC $97.08
- Resistance Level
- AXTA $33.42
- BPMC $101.97
- Average True Range (ATR)
- AXTA 0.86
- BPMC 4.07
- MACD
- AXTA 0.15
- BPMC 0.54
- Stochastic Oscillator
- AXTA 70.25
- BPMC 64.34
About AXTA Axalta Coating Systems Ltd.
Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific, and Latin America.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.